Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse ...
Endocrinology Advisor9d
EVT-Treated Patients With MCA MeVO: High Comorbidity Burden and Worse Outcomes
Participants had a first-ever stroke and prestroke functional independence (modified Rankin Scale [mRS]: 0-2) and received EVT for MeVO in the MCA territory from 2015 to 2021. Comorbidity burden was ...